{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"462","upperLimit":"462","value":"462"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Apparent (Extravascular) Clearance (CL/F)","dispersionType":"Full Range","groups":[{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG000","title":"Cohort 5: N-803 - SQ 10 ug/kg"},{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG001","title":"Cohort 6: N-803 - SQ 15 ug/kg"}],"paramType":"MEAN","populationDescription":"In addition, 6 out of 7 SC patients (Cohorts 5 and 6) had insufficient measurable post-tmax sampling to allow for evaluation of the terminal phase-dependent PK parameters (ie, t½, CL/F, Vz/F, AUC0-168, AUC0-∞).","reportingStatus":"POSTED","timeFrame":"PK timepoint up to 72 hours +/- 6 hours","title":"Characterization of the Pharmacokinetic Profile - Apparent (Extravascular) Clearance (CL/F)","type":"SECONDARY","unitOfMeasure":"mL/hr/kg"}